** Shares of biopharma firm Travere Therapeutics TVTX.O rise 3.5% to $20.42

** TVTX says it submitted a marketing application to the U.S. FDA for co's drug, Filspari, for treatment of a rare kidney scarring disease called focal segmental glomerulosclerosis

** Co expects to receive regulatory decision in Q2

** Filspari is currently approved to slow decline in kidney function in adults with immunoglobulin A nephropathy, a leading cause of kidney failure

** Up to last close, TVTX has more than doubled in the past 12 months

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))